Ontogeny of Recognition Specificity and Functionality for the Broadly Neutralizing Anti-HIV Antibody 4E10 by Finton, Kathryn A. K. et al.
 
Ontogeny of Recognition Specificity and Functionality for the
Broadly Neutralizing Anti-HIV Antibody 4E10
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Finton, K. A. K., D. Friend, J. Jaffe, M. Gewe, M. A. Holmes, H.
B. Larman, A. Stuart, et al. 2014. “Ontogeny of Recognition
Specificity and Functionality for the Broadly Neutralizing Anti-
HIV Antibody 4E10.” PLoS Pathogens 10 (9): e1004403.
doi:10.1371/journal.ppat.1004403.
http://dx.doi.org/10.1371/journal.ppat.1004403.
Published Version doi:10.1371/journal.ppat.1004403
Accessed February 17, 2015 4:25:23 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:13347649
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAOntogeny of Recognition Specificity and Functionality
for the Broadly Neutralizing Anti-HIV Antibody 4E10
Kathryn A. K. Finton
1, Della Friend
1, James Jaffe
1, Mesfin Gewe
1, Margaret A. Holmes
1{,
H. Benjamin Larman
2, Andrew Stuart
3, Kevin Larimore
4, Philip D. Greenberg
4,5,6, Stephen J. Elledge
2,
Leonidas Stamatatos
3,7, Roland K. Strong
1*
1Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, 2Department of Genetics, Harvard University
Medical School, and Division of Genetics, Howard Hughes Medical Institute, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, 3Seattle
Biomedical Research Institute, Seattle, Washington, United States of America, 4Department of Immunology, University of Washington, Seattle, Washington, United States
of America, 5Department of Medicine, University of Washington, Seattle, Washington, United States of America, 6Program in Immunology, Cancer Research Division,
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, 7Department of Global Health, University of Washington, Seattle, Washington,
United States of America
Abstract
The process of antibody ontogeny typically improves affinity, on-rate, and thermostability, narrows polyspecificity, and
rigidifies the combining site to the conformer optimal for binding from the broader ensemble accessible to the precursor.
However, many broadly-neutralizing anti-HIV antibodies incorporate unusual structural elements and recognition
specificities or properties that often lead to autoreactivity. The ontogeny of 4E10, an autoreactive antibody with
unexpected combining site flexibility, was delineated through structural and biophysical comparisons of the mature
antibody with multiple potential precursors. 4E10 gained affinity primarily by off-rate enhancement through a small number
of mutations to a highly conserved recognition surface. Controverting the conventional paradigm, the combining site
gained flexibility and autoreactivity during ontogeny, while losing thermostability, though polyspecificity was unaffected.
Details of the recognition mechanism, including inferred global effects due to 4E10 binding, suggest that neutralization by
4E10 may involve mechanisms beyond simply binding, also requiring the ability of the antibody to induce conformational
changes distant from its binding site. 4E10 is, therefore, unlikely to be re-elicited by conventional vaccination strategies.
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Introduction
An effective HIV vaccine will likely need to elicit broadly-
neutralizing antibodies (bnAbs) that target the viral envelope
protein (Env) as part of a protective immune response [1–6]. Env-
derived and reverse-engineered immunogen-based vaccines, how-
ever, have consistently failed to elicit bnAbs. Possible explanations
include that: (1) immunogens may be unable to bind germline-
encoded precursors (GEPs) of bnAbs with sufficient affinity to
initiate B cell activation and affinity maturation, which has a
,micromolar threshold [7–9]; (2) rearranged VH and VL genes
compatible with the development of bnAbs may not be common
in human or animal model vaccinee GEP repertoires; (3) some
bnAbs are autoreactive, which hinders their elicitation through
self-tolerance mechanisms; (4) the unusual characteristics inherent
to bnAbs, such as long complementarity determining regions
(CDRs), functionally-required polyspecificity, and a high degree of
somatic mutation (typically observed in Abs elicited in response to
chronic infections, including bnAbs), may not be easily achieved
through conventional vaccination strategies; (5) imperfect immu-
nogens may elicit off-target (non-neutralizing or non-Env) or
humoral responses with limited breadth; and, finally, (6) neutral-
ization mechanisms may involve complexities beyond simply
binding a particular epitope on Env (e.g., inducing specific
conformational changes), which may be difficult to recapitulate,
since selective expansion of particular B cell clones is based solely
on BCR binding properties, not higher-order functionalities
[10,11].
The bnAb 4E10, the focus of our studies, has a conserved, linear
epitope (core epitope:
671NWF
D/NIT
676) immediately adjacent to
the viral membrane in the Env gp41 subunit membrane proximal
external region (MPER) [12,13]. While 4E10 displays admirable
breadth [14], has been the target of a successful design effort to
reverse-engineer tight-binding immunogens [15], has recognizable
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and arguably does not require a high degree of polyspecificity to
neutralize HIV [17,18], its viability as a vaccine target is
hampered by limited potency, demonstrated autoreactivity and
exceptional combining site flexibility [17,19,20]. The neutraliza-
tion mechanism of 4E10 also has not been clearly defined and may
involve higher order effects [17,21,22]. The ontogeny of 4E10,
therefore, must be elucidated in order to understand how these
properties were acquired and to what degree they impose
constraints that might hinder re-elicitation by vaccination.
Mutations acquired during Ab maturation occur preferentially in
the CDRs, which make up the six loops (CDRs 1, 2, and 3 on the
heavy (HCDRs) and light (LCDRs) chains) comprising the
combining site [23,24]. CDRs are responsible for the majority of
direct contacts to an antigen, as opposed to the intervening
framework regions (FWRs), which form the immunoglobulin b-
sheet structure stabilizing the combining site, helping define CDR
loop conformations. While CDR mutations are typically thought to
more directly affect antigen binding and neutralization, bnAbs
consistently depend on FWR substitutions to a surprising degree,
though 4E10 is an exception to this exception [4]. bnAbs are
notorious for their high degree of somatic hypermutation, the
product of a long process of affinity maturation against a rapidly
mutating virus during a persistent, chronic infection [25]. While
typical affinity-matured Abs have acquired 15 to 20 VH mutations,
bnAbs accumulate up to 100 VH mutations [4]. These mutations
are crucial because reversion to germline sequences drastically
reduces epitope affinity and neutralization potency and breadth. In
many cases, bnAb GEPs are unable to bind Env, though the actual
eliciting isolate may not be known [26–31]. In addition, bnAbs can
containextraordinarily longHCDR3s, up to 33 residues longversus
an average of 13 for non-HIV bnAbs [32,33]. Using phylogenet-
ically-inferred GEP sequences [16,34] (Fig. 1), 4E10 has acquired
between 33 and 35 mutations during maturation, 20 to 22 in VH,
depending on gene segment selection, and 13 in VL, and has an
HCDR3 22 residues long, values at the less exceptional end of the
bnAb spectrum and not unheard of for conventional Abs.
Affinity-matured Abs display univalent equilibrium binding
constants (KD) for their cognate antigens, typically ranging from
10
26 to 10
210 M, that are orders-of-magnitude stronger than their
GEPs [35]. Multiple approaches, including computational analy-
ses and biophysical comparisons of affinity-matured Abs and their
associated GEPs, have generated a consensus model for the
molecular mechanism of affinity maturation [36–47], perhaps
better understood as binding optimization, that traces its roots
back to Pauling [48]. In the consensus model, the antigen
specificities of the naı ¨ve, germline-encoded repertoire, while
diverse and extensive, are further extended by encoding a high
degree of polyspecificity into GEPs. This is accomplished partly
through increased combining site plasticity in GEPs, more
formally stated as the ability of GEP CDRs to dynamically sample
a broader ensemble of structural conformers. In response to
immunogen stimulation, Ab binding properties are iteratively
optimized through cycles of somatic hypermutation and selection,
resulting in improved binding affinities, kinetics and thermody-
namics. While mutations have been observed to improve or add
direct contacts to antigen, typically improving enthalpies of
interaction and off-rates (kd), a majority of measurably favorable
mutations do not directly contact antigen. These mutations
indirectly optimize binding by: (1) increasing shape complementarity
Author Summary
4E10 is an antibody that neutralizes a broad variety of HIV
strains. However, 4E10 is uncommon in infected patients
and has not been successfully elicited by any vaccine
approach attempted. Hurdles to re-eliciting 4E10 include
the accumulation of many mutations during development,
demonstrated reactivity against host proteins and signif-
icant structural flexibility. Lacking a confirmed sequence
for precursors of 4E10, we studied the recognition and
biophysical properties of an ensemble of eight of the
likeliest candidates. Surprisingly, 4E10 gained host reactiv-
ity and structural flexibility, but lost stability during
development when compared to candidate precursors.
However, recognition of HIV was remarkably conserved,
despite a considerable improvement in binding. Since
these results run counter to those expected from
conventional vaccination protocols, 4E10 is unlikely to
serve as the basis of a useful HIV vaccine.
Figure 1. Prediction of an ensemble of 4E10 GEPs. Sequences of 4E10 VL (top line) and VH (bottom two lines) domains are shown, with CDRs
indicated by a blue overscore. Predicted somatic mutations are colored red in the 4E10 sequence, and the corresponding unmutated GEP residues
are shown below in grey (unchanged positions are not shown for clarity). All GEP VL domains are comprised of the IGKV3-20*01/IGKJ1*01 gene
segment combination. Each GEP VH domain comprises the IGHV1-69*06 V gene segment plus one of six D gene segments (listed to the left of the
corresponding GEP in the blue boxed field), and either the IGHJ4*02 (resulting sequence differences shown in purple and bolded) or IGHJ1*01
(resulting sequence difference shown in blue and bolded) gene segment, yielding an ensemble of 12 GEPs in toto. GEP shorthand numbering is
shown in grey (GEPs 1 to 6) and blue (GEPs 7 to 12) beside the corresponding D plus J gene segment combination sequence differences from 4E10,
occurring in HCDR3. Inset (lower right): HCDR3 sequences from candidate 4E10 GEPs, determined through deep sequencing of naı ¨ve B cell germline
IgH genes from four uninfected individuals [16], show the degree of variability seen in potential 4E10 precursors present in naı ¨ve repertoires. Each
germline rearrangement uses the IGHV1-69 and IGJH1 or IGJH4 gene segments. Amino acids in red designate sequence differences between GEP and
4E10. The number of nucleotide changes needed to achieve these somatic mutations is 16 for donor 1, 17 for donor 2 and 18 for donors 3 and 4.
doi:10.1371/journal.ppat.1004403.g001
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structure; (2) increasing antibody stability, typically measured as
solution thermostabilities (Tm), thus compensating for deleterious
effects of other mutations that improve affinity; and (3)
structurally rigidifying the combining site conformer optimal for
binding antigen from the accessible ensemble. Rigidifying the
combining site can affect measured interaction parameters in
different ways depending on the mechanism of binding. The two
mechanistic extremes are known as ‘‘conformer-selection’’ and
‘‘instructive-encounter’’, or ‘‘induced-fit’’, binding. In conformer-
selection mode, binding does not occur until the compatible
conformer is adopted. Rigidification of the binding site through
mutation then typically improves entropies of interaction and on-
rates (ka). In instructive-encounter mode, initial binding occurs to
sub-optimal conformers which affects the rate of interchange with
the optimal conformer. Rigidification of the binding site through
mutation then typically improves affinity through changes
distributed over kd and ka. However, the consensus of studies of
binding proteins and enzymes suggests that conformer selection is
the preeminent recognition mechanism [49].
Surprisingly, comparisons of the bound and unbound structures
of 4E10 revealed that this affinity-matured bnAb incorporates
considerable HCDR conformational flexibility [17], in excess of
what has been observed in most other antibodies, mature or GEP,
suggesting that the ontogeny of 4E10 may be an exception to the
consensus model and may pose unique challenges as a vaccine
target. In order to fully understand the ontogeny of this unique
bnAb and consequences for vaccine development, we characterized
the unbound and complex crystal structures, and the functional and
bindingproperties,of4E10 and anensemble ofitsmost likelyGEPs.
GEPs showed detectable, but extremely weak, binding to soluble
Env gp140s and extremely limited neutralization potency, though
some reverse engineered epitope-scaffolds (ESs) showed robust GEP
affinities, well above the B cell activation threshold. 4E10 and GEP
paratopes displayed a remarkable degree of structural conservation
in the antigen-bound state, with little improvement in overall shape
complementarity. Multi-log improvements in affinity for ESs were
the result of improved off-rates or combined improvements in on-
and off-rates, with a small number of enhanced contacts to antigen
observed in the crystal structures. However, minimal mutations of
GEP sequences to include these enhanced direct contacts only
marginally increases affinity. FWR mutations had little discernable
effect on global or local structure. Controverting the consensus
model of ontogeny, 4E10 thermostability was appreciably worse
thanitsGEPs;while4E10andGEPsdisplayedsimilarlyconstrained
VH/VL interdomain movements upon binding, 4E10 maturation
involved negligible combining site rigidification, with both 4E10
and GEP HCDRs sampling extensive conformer ensembles. The
narrowing of polyspecificity assumed to concur with maturation was
not observed with 4E10, as both 4E10 and its GEPs showed similar
patterns of limited polyspecificity to a phage-displayed human
peptidome (Phage Immunoprecipitation Sequencing; PhIP-Seq)
[50]. While 4E10 is demonstrably autoreactive, GEPs exhibited a
distinct profile of autoantigen recognition by PhIP-Seq. When
combined, these results inform efforts to re-elicit 4E10 by
vaccination and its mechanism of neutralization.
Figure 2. Biophysical and functional characterization of an ensemble of 4E10 GEPs. (A) CD melting curves are shown for 4E10 andGEPs with
Tm values, determined as the inflection point of the sigmoidal melting curve, indicated by a black line (4E10) or a shaded grey box (GEPs). (B)
Neutralizationpotencies areshown for 4E10 IgG(0.2 mM),4E10 FvandGEPs (1 mM)against cladeA (Q461.d1,Q461.e2)andB (SF162)HIV-1isolatesusing
standard TZM-bl assays. (C) Double-referenced SPR sensorgrams are shown for the binding of 4E10 and GEPs (300 nM duplicates) interacting with chip-
coupled gp1403.( D) KDs fortheinteractionof4E10 or GEPs withES T117areplotted as ka vs. kd, with KD isotherms indicatedbydashedlinesandlabeled.
Due to weak binding and fast kinetics, KDs between GEPs and the T72, T344, and T93 ESs could only be analyzed by equilibrium measurements; their
values range from 1 to 10 mM, falling within the grey shaded region. The purple triangles show the T117 affinity shift between 4E10 and GEPs, with the
sides parallel to the X and Y axes of each triangle highlighting the association and dissociation rate components, respectively.
doi:10.1371/journal.ppat.1004403.g002
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Prediction of an ensemble of likeliest GEP sequences
Lacking access to the original donor, identification of a single
GEP sequence with high confidence for many bnAbs, including
4E10, is complicated by extensive editing and TdT N-nucleotide
insertion during rearrangement [26], leading to our decision to
study an ensemble of the 12 likeliest candidates (Fig. 1). Due to
the prediction that the sequence differences introduced by
alternate heavy chain J gene segments may not affect any
discernable GEP property, the initial ensemble was limited to
eight GEPs (IGHJ4*02 paired with all six D segments plus
IGHJ1*01 paired with IGHD1-1*01 and IGHD6-19*01), with
the intention of generating additional GEPs if the IGHJ4*02/
IGHJ1*01 substitution exhibited any differences in structure or
binding properties on the IGHD1-1*01 or IGHD6-19*01
backgrounds. These eight GEPs also recapitulated some of the
variability seen in potential 4E10 GEPs identified by deep
sequencing of uninfected individuals (Fig. 1) [16], providing an
additional justification for studying the ensemble. However,
GEPs in our ensemble differed from one another by no more
than four mutations, though the mutations were quite non-
conservative.
GEP protein production and validation
GEPs were engineered as cleavable, single-chain, variable
domain cassette (Fv; VH+VL) constructs to ease expression,
analysis, and crystallization and to prevent monobody-diabody
interchange, following protocols developed for 4E10 [18]. The
prior study confirmed that these Fv constructs retained the
structural and binding properties of Fab fragments of intact 4E10.
All eight GEP Fvs expressed at high levels as bacterial inclusion
bodies and, in all but one case (GEP 5), were refolded in vitro with
what in our experience were exceptionally high efficiencies of 20 to
40%. GEP 5 was not included in subsequent experiments because
its extremely poor in vitro refolding efficiency suggested that this
was not a viable pairing. GEP constructs were stable and
monodisperse in solution, running exclusively as monomers by
size exclusion chromatography (SEC). Reduced/non-reduced
PAGE analysis of GEPs confirmed purity and proper disulfide
bond formation. GEP Tm values (Fig. 2A), determined by circular
dichroism (CD) spectroscopy as previously described [18],
narrowly ranged from 64.2uC to 67.0uC, showing that GEP Fvs
were well folded, but had even higher Tm values than 4E10 Fv
(52.8uC).
GEP neutralization potencies were dramatically reduced
The neutralization potency of GEPs was tested against clade A
(Q461.d1, Q461.e2 [51]) and B (SF162 [52]) HIV-1 isolates using
standard TZM-bl assays (Fig. 2B) [53]. Overall, GEP Fv
potencies were markedly reduced in comparison with 4E10 Fv.
GEPs displayed only very weak and likely insignificant neutrali-
zation potencies, though with a trend of greater effect against the
clade A isolates, particularly the neutralization-sensitive strain
Q461.d1, and with GEP 1 and GEP 7 showing marginally better
potencies across tested isolates.
Figure 3. SPR sensorgrams of the interactions between 4E10 and the indicated ESs are shown. Time (in seconds) is plotted on the x-axis
and SPR response (in RUs) is plotted on the y-axis. Double-referenced binding data are shown in black with corresponding kinetics fits to the data
shown in red. Details of the experiments are given in Table 1.
doi:10.1371/journal.ppat.1004403.g003
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with reduced affinities
In order to characterize the change in binding properties during
4E10 ontogeny, the binding of 4E10 and GEP Fvs to three (SF162,
SF162
K160N and Q461.e2) soluble Env gp140 trimers (gp1403)
[54] and four engineered 4E10 ES immunogens (T72, T93, T117
and T344) [15,55] was evaluated by surface plasmon resonance
(SPR) interaction analysis (Figs. 2C, 2D, Figs. 3–7, Table 1).
Isolates and ESs were selected to span a range of binding
properties, where previous studies had shown 4E10 bound a free
peptide spanning its linear epitope with a KD of 12 nM, SF162
gp1403 with a KD of 98 nM, and ESs with KDs of either #10
picomolar (T117) or ,100 picomolar (T72, T93 and T344)
[15,18,55]. All seven GEPs showed unquantifiably weak, but
detectable binding to chip-coupled clade A (Q461.e2) and clade B
(SF162, SF162
K160N) gp1403 and T72, T93, and T344 in
qualitative SPR analyses, with KDs all estimated to be well above
the ,micromolar B cell activation threshold. Quantitative SPR
analyses of GEPs binding to T117 showed KDs ranging from the
low nanomolar to low micromolar range. 4E10 interactions with
ESs ranged from 100- to 10,000-fold stronger than GEPs, which
was qualitatively consistent with the observed difference in 4E10
versus GEP interactions with gp1403. Since the GEP/gp1403
interactions were too weak to quantitate, peptide binding studies
were not performed on the expectation that they would also be too
weak to measure accurately. Five GEPs (1, 2, 3, 7 and 8) bind
T117 with nearly identical behavior, including GEP 1 and GEP 7,
which differ only by alternate J segment utilization, showing that
the two incorporated mutations did not affect binding, so no
further IGHJ1*01 GEPs were produced for study. GEP 4 and
GEP 6, which both incorporate differences from G96H in 4E10 (A
or V), showed approximately 10-fold (GEP 4) or 100-fold (GEP 6)
reductions in affinity relative to the cluster of other GEPs.
Kinetically, the five clustering GEPs (1, 2, 3, 7 and 8) showed
affinity reductions for T117 relative to 4E10 overwhelmingly
through faster off-rates (kds). GEPs 4 and 6, in addition to
comparable increases in kd, also showed progressive reductions in
on-rates (kas).
4E10- and GEP-ES complex structures show binding site
conservation
In order to shed light on potential structural differences
accounting for reduced GEP binding affinities, crystal structures
of GEP 1, 2 and 7 in complex with T117 were determined at
resolution values of 2.9 A ˚, 1.8 A ˚, and 3.1 A ˚ respectively, rebuilt
and refined with good statistics (Table 2), and compared to two
reference 4E10/antigen complex structures: 4E10 bound to an
epitope peptide (2FX7.pdb [12]) or a related ES, T88 (3LH2.pdb
[15]). Superpositions showed that almost all direct contacts to the
core epitope (NWFDIT) and epitope conformation are conserved
between 4E10 and GEP complexes to a remarkable degree
(Fig. 8, Tables 3 and 4). Only six of the 35 predicted somatic
Figure 4. SPR sensorgrams of the interactions between ES T72 and the indicated GEPs (left plots) and the analysis of equilibrium
responses versus concentration (right plots). Details of the experiments are given in Table 1.
doi:10.1371/journal.ppat.1004403.g004
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core epitope: Y/K32L, S/Q93L, T/S31H, I/V51H, F/L54H and
T/I56H. However, residues at two of these positions (93L, 51H)
contacted the epitope solely through main-chain interactions, which
werenot affected bythemutated side-chains. Replacementsat three
other positions (31H, 54H, 56H) nearly perfectly recapitulated
contacts, also conserving the interface. The 4E10 and GEP
paratope/epitope interface is largely hydrophobic, thus binding is
mainly mediated by Van der Waals contacts and desolvation
entropy, which is conserved through equivalent positioning of
nonpolar groups. This was reflected in the close concordance
between the surface areas (SA) buried in the complexes by core
epitope and the corresponding shape complementarity (Sc) [56]
between Ab and core epitope. Only two somatic mutations were
predicted to contribute to a stronger binding interaction. The Y/
K32L mutation replaces a hydrogen bond involving the tyrosine
hydroxyl with a salt bridge. The P/L95H mutation, involving non-
contacting residues, restructured LCDR3 to reposition the side-
chain of the conserved serine at 94L from a non-contacting position
in GEPs to one contributing a hydrogen bond in 4E10 complex
structures. However, the Y/K32L-P/L95H double mutation made
on a GEP 1 background (GEP 1
m) did not affect Tm,o n l y
marginally increased affinity by about three-fold, and did not
improve neutralization potency (Figs. 2A, 2D, 6 and Table 1),
arguing that affinity and neutralization are largely influenced by
somatic mutations through indirect effects beyond the ability to
adopt the optimal binding conformer.
GEP structures revealed that structural plasticity was
retained during affinity maturation
In order to determine whether the 4E10 combining site
rigidified during affinity maturation, undergoing binding site
preconfiguration, the crystal structures of GEP 7 and GEP 1 were
determined in the unbound state at resolution values of 1.9 A ˚ and
1.7 A ˚ respectively, rebuilt and refined with good statistics
(Table 2), and compared to the unbound structure of 4E10
(4LLV.pdb [17]). Superpositions of 4E10 and GEP bound and
unbound structures showed that interdomain movements, while
present, were limited compared to CDR rearrangements (Fig. 9),
and that 4E10 retained at least as much CDR flexibility as was
present in GEPs, particularly in HCDR2 and HCDR3, while
LCDRs were relatively constrained (Figs. 10A and 10B).
Calculated root mean square deviations (RMSDs; Fig. 10C)o f
VH and VL superpositions, with and without CDRs, confirmed
that while the FWR regions of GEPs and 4E10 were nearly
identical, the bulk of rearrangements observed during binding
occurred in HCDRs, with 4E10 movements as large, or larger,
than observed in GEPs. LCDR movements, while much smaller
overall, contributed less to rearrangements in 4E10 than GEPs,
suggesting some minimal degree of rigidification during matura-
tion. Comparison of the surfaces directly contacting epitopes
(Movies S1 and S2) showed that GEPs retained higher degrees of
structural conservation than 4E10 between the bound and
unbound states. These analyses need to be interpreted cognizant
of the constraints imposed by crystallization, which involved
Figure 5. SPR sensorgrams of the interactions between ES T93 and the indicated GEPs (left plots) and the analysis of equilibrium
responses versus concentration (right plots). Details of the experiments are given in Table 1.
doi:10.1371/journal.ppat.1004403.g005
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contacts between structures. However, these caveats were mini-
mized by comparing multiple structures with multiple copies per
asymmetric unit.
Engineered ESs can make extensive contacts outside of
the targeted epitope
The goal of reverse engineering an Ab is to scaffold the desired
epitope to re-elicit Abs that solely recognize the epitope [6,57].
However, the 4E10 linear epitope, as currently defined, is smaller
than typical Ab/antigen interfaces, which poses the design
challenge of isolating humoral responses to the epitope and not
contiguous scaffold surfaces. Previous crystal structures of 4E10/
ES complexes showed that many ESs achieved this goal well,
including T93 [15,55]. However, GEP/T117 complex structures
reported here showed extensive GEP/scaffold contacts (SA for
GEP2 contacts to scaffold minus epitope=308 A ˚ 2)( Fig. 11). A
dominant feature of these interactions was the binding of the side-
chain of the GEP-specific residue F54H in a deep hydrophobic
cleft of the T117 scaffold protein, a putative phosphotransferase
from S. typhimurium. These additional contacts raise the concern
that Abs elicited by T117 immunizations may have off-target (non-
Env) specificities. Nevertheless, the T117 scaffold is highly
complementary to 4E10 (Sc for GEP2/T117=0.69), which may
help explain the increased affinity of T117 for 4E10 and GEPs,
and may be ideal for preferentially targeting GEPs through the
F54H interaction (F54H is present in the heavy chain gene used by
all GEPs). The additional T117 contacts appear to have had the
effect of increasing the affinity for T117 over other ESs by two
orders of magnitude for 4E10 and by one to three orders of
magnitude for the GEPs. However, structural superpositions show
that these extra Ab/scaffold interactions do not affect Ab/epitope
interactions, or the structure of the epitope in the complexes,
which are highly conserved (Fig. 8B).
GEPs displayed a similar degree of limited polyspecificity
to 4E10, but different autoreactivity
A validated phage-displayed library consisting of 413,611
overlapping 36-mer peptides spanning the entire human proteome
combined with phage immunoprecipitation sequencing (PhIP-Seq)
was used to assess the polyspecificity and autoantigen recognition
profiles of GEPs in comparison to 4E10 [17,50] (Fig. 12A,
Tables 5, 6, and 7). GEP 2 and GEP 4 were selected to represent
both the clustering (GEP 2) and 96H mutant (GEP 4) GEPs, and
an affinity-matured, murine anti-canine CD28 Ab, 1C6 [58], was
included for comparison (Fig. 12A, Table 8). The top hit in the
4E10 Fv PhIP-Seq analysis reported here, a peptide derived from
the type 2 inositol 1,4,5-trisphosphate receptor (IP3R), matches the
top hit from the previous PhIP-Seq analysis of IgG 4E10 [17].
However, overall scores were considerably reduced in the PhIP-
Seq analysis of 4E10 as an Fv construct versus intact IgG (replicate
average 2Log10 P-values for the top ten scoring peptides of 35.3
Figure 6. SPR sensorgrams of the interactions between ES T117 and the indicated GEPs are shown. Binding data are shown in black with
the kinetic fits to the data shown in red. Details of the experiments are given in Table 1.
doi:10.1371/journal.ppat.1004403.g006
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accessibility of coupled Fv relative to IgG, an increased chance of
inactivating Fv versus IgG during chemical coupling, and the
inherent increase in local avidity of bivalent IgG versus univalent
Fv on potentially sparsely-coupled beads. Given these caveats,
overall scoring behavior was very similar across the Fvs tested,
with 4E10 and 1C6, the affinity-matured Abs, showing the highest
average scores. GEP 4 and 1C6 showed the largest number of
high-scoring hits, with 61 and 194 peptides with replicate-
averaged 2Log10 P-values of $4.0 respectively; 4E10 and
GEP2 had 12 and 20 peptides, respectively, scoring $4.0.
Qualitatively, the results were not dramatically different, but with
GEP 4 and 1C6 showing nominally greater spreads of top-scoring
peptides rising above the bulk responses. None of the top-scoring
three-dozen 4E10 peptides appeared in the top three-dozen hits
from either GEP; however two of the top-scoring dozen GEP
peptides (derived from zinc finger Ran-binding domain-containing
protein 3 or hyaluronidase-3 isoform 1 precursor) were in common
between GEP 2 and GEP 4, scoring 1 and 12 (GEP 2) and 4 and 2
(GEP 4), respectively. However, no common peptide motifs could
be identified within or between Fv results. None of the IP3R
peptides scored in the top 65,000 GEP hits. While 1C6 showed the
highest scoring spread of top hits (replicate average 2Log10 P-
values for the top ten scoring peptides of 12.14 to 30.9), the top ten
scoring peptides displayed a considerably higher average hydro-
phobic character (W), with average W values of: 4E10=0.37; GEP
2=0.42; GEP 4=0.45; 1C6=0.71 (higher values are more
hydrophobic). Using relative hydrophobicity of the top-scoring
PhIP-Seq peptides as a surrogate measure of the overall
hydrophobicity of the combining site was consistent with the
structures of the Abs (Fig. 12B), where the 1C6 combining site is
structured as a large, broad, very hydrophobic concavity and 4E10
and its GEPs sporting smaller, convex hydrophobic surfaces.
Pre-binding of 4E10 at the MPER affects the binding of
bnAb b12 at the CD4 binding site
In order to test the hypothesis that 4E10 may induce global
conformational changes in gp1403 as part of a higher-order
neutralization mechanism [17,21], consistent with downstream
effects such as gp120 release, binding of Abs to epitopes distant
from the MPER (the V3 loop, by 447-52D [59], and the CD4
binding site, by b12 [60]) was assayed by SPR in the presence or
absence of saturating 4E10 (Fig. 13). The qualitative results show
that 4E10 pre-binding does not affect 447-52D binding to the
flexible, extended V3 loop, but does alter the association kinetics of
b12 at the CD4 binding site, suggesting that 4E10 binding induced
global conformational changes in gp1403 registering at distant
sites. Since b12 dissociation kinetics were unaffected, 4E10 did not
preclude achieving a similar b12 bound-state conformation.
Discussion
Reverse engineered ESs are ideal reagents for studying the
binding properties of GEPs. Where peptides and Env do not
Figure 7. SPR sensorgrams of the interactions between ES T344 and the indicated GEPs (left plots) and the analysis of equilibrium
responses versus concentration (right plots). Details of the experiments are given in Table 1.
doi:10.1371/journal.ppat.1004403.g007
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across the GEP ensemble, allowing for the biophysical character-
ization of 4E10 ontogeny by using ESs to compare 4E10 and GEP
binding kinetics and bound-state crystal structures. Consistent with
current theory and previous results comparing GEPs with matured
bnAbs or other Abs, 4E10 displays orders-of-magnitude better
affinities than candidate GEPs for both Env gp1403 proteins and
engineered ESs. This gain in affinity is potentially sufficient to
account for the concurrent gain in neutralization potency over
GEPs. Previous results showing minimal contributions from FWR
mutations [61] and comparisons of complex structures of 4E10
with GEP/T117 complex structures, which showed near-complete
conservation of the recognition interface (Fig. 8), argue that
affinity maturation was likely due, at least in part, to the small
number of somatic mutations in the CDR regions, e.g. 32L and
95H, that add or improve direct contacts to epitope. This limited
number of mutations is presumably readily achievable during
conventional vaccination. Based on PhIP-Seq peptidome binding
results (Fig. 12A), 4E10 and GEPs have distinct autoantigen
profiles, suggesting that 4E10 autoreactivity was acquired during
ontogeny and not inherent in GEPs, consistent with recognizable
GEPs populating naı ¨ve repertoires of mature B cells at relatively
high frequencies [16]. Among ESs, T117 in particular interacts
with GEPs sufficiently strongly to drive B cell activation and
maturation (Fig. 2D) and selectively interacts with GEP-specific
structural features, e.g. F54H (Fig. 11). These aspects of 4E10
combine to seemingly argue that 4E10 ontogeny follows a
relatively short path and that directed re-elicitation of 4E10, and
perhaps other bnAbs, may be an achievable goal.
In many aspects, however, 4E10 ontogeny appears more
convoluted. Contrasting with the consensus model of Ab ontogeny
and results from other systems [38], 4E10 is considerably less
thermostable than GEPs, which was difficult to account for only
from static views of structures. This lowers the headroom available
to tolerate mutations that increase affinity or potency that
otherwise might degrade stability, potentially adding a significant
hurdle to re-elicitation of 4E10, but clearly does not limit the
ability of 4E10 to bind to or neutralize HIV. The conformer
ensemble sampled by GEP combining sites echoes the startling
plasticity of 4E10, with structural comparisons of bound versus
unbound states (Figs. 9 and 10) showing perhaps a small degree
of 4E10 LCDR rigidification, but an increase in the conformer
ensemble sampled by the HCDRs. This directly contradicts the
consensus model, and specific examples [40], of Ab maturation,
showing alternatively that preconfiguration of 4E10 does not occur
during, or contribute to, affinity maturation. HCDR flexibility is
highlighted by F29H, which is able to flip out into solvent in the
unbound 4E10 and GEP 1 structures, allowing HCDR1 to
dynamically sample multiple conformers. A high number of
conserved glycine residues may contribute to 4E10 and GEP
HCDR mobility. The reduced affinities due to decreased kas
(Fig. 2D), relative to the clustering GEPs, of GEP 4 and 6 with
non-glycine residues at position 96H, predicted to restrict HCDR3
conformer sampling, suggests that HCDR3 mobility was needed
to achieve the bound-state conformation with optimal kinetics by
destabilizing non-optimal conformers. Retention of significant
combining site plasticity also strongly argues for a functional role
other than polyspecificity, which is unremarkable in comparison to
Figure 8. The epitope binding site is conserved between 4E10 and its GEPs. (A) Residues from the combining sites of 4E10 and GEPs,
superimposed based on bound-state structures, contacting the NWFDIT core epitope (shown in a cartoon representation as a grey corkscrew) are
shown in a stereo view. 4E10 and GEP residues are shown in licorice stick representation and colored as follows: 4E10 Fv (3LH2.pdb, in complex with
ES T88) in purple, 4E10 Fab (2FX7.pdb, in complex with an extended 16-mer NWFDIT-containing peptide) in orange, GEP 1 in yellow, GEP 2 in cyan,
and GEP 7 in red. Analyses and depictions were restricted to the core epitope to maximize comparability. Calculated SA buried in the complexes and
Sc between core epitope and Ab are: 4E10 Fab/epitope peptide: SA=355 A ˚2, Sc=0.78; 4E10/T88: SA=367 A ˚2, Sc=0.77; GEP 1/T117: SA=342 A ˚2,
Sc=0.69; GEP 2/T117: SA=305 A ˚2, Sc=0.74; GEP 7/T117: SA=343 A ˚2, Sc=0.66. (B) The NWFDIT core epitope is shown in a licorice stick
representation isolated from the superimposed complex structures, highlighting the high degree of conservation of both the position and
conformation of the peptide across 4E10 and GEP complexes.
doi:10.1371/journal.ppat.1004403.g008
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(Fig. 12A). Minimal focusing of apparent polyspecificity also
contradicts the consensus model, and specific examples [62], of
maturation. Also unexpectedly, the ,100-fold increase in affinity
of 4E10 over GEPs to T117 is through a decreased kd (Fig. 2D),
suggesting that improvements in binding affinity arose from a
more favorable bound state and not a decrease in entropic barriers
imposed by more plastic GEPs. Thermodynamic studies of 4E10
and GEPs were not possible because no single antigen, needed for
valid comparisons, bound to both 4E10 and GEPs with
parameters accessible to measurement. However, while crystal
structures showed a highly-conserved bound state in both 4E10
and GEPs, the small number of improved contacts could not
account fully for the observed improvement in affinity. Compli-
cating this analysis, and its use as a vaccine immunogen, are the
extensive contacts between GEPs, and presumably also 4E10, and
the scaffold of T117 outside of the stabilized MPER epitope
(Fig. 11). The interaction with T117 also highlights another
possibility. The 4E10 combining site extends beyond the minimal,
linear epitope in T117, making contacts to the scaffold. Unless the
MPER epitope forms an isolated structure extended away from
the rest of Env, 4E10 may make contacts to elements of Env
outside of the linear 4E10 epitope, as it does with T117. HCDR
conformer dynamics may therefore be understood as enabling
Table 3. Epitope contacts for 4E10 and GEPs determined from complex crystal structures; electrostatic contacts are bolded;
otherwise, the contacts are mediated by van der Waals interactions.
NWFDIT epitope 4E10 Fab (16-mer peptide) 4E10 Fv (T88) GEP 1 (T117) GEP 2 (T117) GEP 7 (T117)
Asn – – L 32 TYR L 32 TYR L 32 TYR
L9 1T Y R – L9 1T Y R L9 1T Y R L9 1T Y R
L 91 TYR – L 91 TYR L 91 TYR L 91 TYR
L9 2G L Y L9 2G L Y L9 2G L Y L9 2G L Y L9 2G L Y
L 92 GLY L 93 GLN* L 92 GLY L 92 GLY L 92 GLY
L 93 GLN* L9 4S E R L 93 SER* L 93 SER* L 93 SER*
L9 4S E R L 9 4 S E R –––
L 94 SER – – –
Trp H 33 ALA H 33 ALA H 33 ALA H 33 ALA H 33 ALA
H5 0G L Y H5 0G L Y H5 0G L Y H5 0G L Y H5 0G L Y
H 51 VAL* H 51 VAL* H 51 ILE* H 51 ILE* H 51 ILE*
H 52 ILE H 52 ILE H 52 ILE H 52 ILE H 52 ILE
H 56 ILE* – H 56 THR ––
H 56 ILE* H 56 ILE* H 56 THR* – H 56 THR*
– H 58 ASN –––
H5 8A S N H5 8A S N H5 8A S N H5 8A S N H5 8A S N
L9 4S E R L9 4S E R –––
L9 4S E R L9 4S E R – – –
Phe H 47 TRP H 47 TRP H 47 TRP H 47 TRP H 47 TRP
H 100J PHE H 100J PHE H 100J PHE H 100J PHE H 100J PHE
L9 1T Y R L9 1T Y R L9 1T Y R L9 1T Y R L9 1T Y R
L 93 GLN* L 93 GLN* L 93 SER* L 93 SER* L 93 SER*
L9 4S E R L9 4S E R L9 4S E R L9 4S E R L9 4S E R
L9 6S E R L9 6S E R L9 6S E R L9 6S E R L9 6S E R
Asp L 32 LYS* L 32 LYS* L 32 TYR* L 32 TYR* L 32 TYR*
L 32 LYS* L 32 LYS* L 32 TYR* L 32 TYR* L 32 TYR*
Ile H 52 ILE H 52 ILE H 52 ILE H 52 ILE H 52 ILE
H 54 LEU* H 54 LEU* H 54 PHE* H 54 PHE* H 54 PHE*
H 56 ILE* H 56 ILE* H 56 THR* – H 56 THR*
Thr H 31 THR* H 31 THR* H 31 SER* H 31 SER* H 31 SER*
H 32 TYR H 32 TYR H 32 TYR H 32 TYR H 32 TYR
H3 3A L A H3 3A L A H3 3A L A H3 3A L A H3 3A L A
H 52 ILE H 52 ILE H 52 ILE H 52 ILE H 52 ILE
H 95 GLU H 95 GLU H 95 GLU H 95 GLU H 95 GLU
H9 5G L U H9 5G L U H9 5G L U H9 5G L U H9 5G L U
H 100F PRO H 100F PRO H 100F PRO H 100F PRO H 100F PRO
Asterisks indicate residues that differ between GEPs and 4E10.
doi:10.1371/journal.ppat.1004403.t003
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PLOS Pathogens | www.plospathogens.org 12 September 2014 | Volume 10 | Issue 9 | e1004403Table 4. Additional contacts between GEPs and the scaffold moiety of ES T117 outside of the grafted 4E10 epitope.
Epitope-scaffold T117 GEP 1 GEP 2 GEP 7
8 ALA H 100E LYS H 100E LYS H 100E LYS
56 ARG H 54 PHE H 54 PHE H 54 PHE
H5 5G L Y H5 5G L Y H5 5G L Y
– H 56 THR H 56 THR
– H 56 THR H 56 THR
60 PHE H 54 PHE H 54 PHE H 54 PHE
H5 5G L Y H5 5G L Y H5 5G L Y
– H 56 THR –
62 THR H 54 PHE H 54 PHE H 54 PHE
64 LEU H 53 ILE H 53 ILE H 53 ILE
73 ILE H 54 PHE H 54 PHE H 54 PHE
75 HIS H 54 PHE H 54 PHE H 54 PHE
100 ALA H 53 ILE H 53 ILE H 53 ILE
H 54 PHE H 54 PHE H 54 PHE
A 73 LYS H 73 LYS H 73 LYS
101 GLY H 73 LYS H 73 LYS H 73 LYS
125 ASN H 100F PRO H 100F PRO H 100F PRO
H 100E LYS H 100E LYS H 100E LYS
127 LEU H 53 ILE H 53 ILE H 53 ILE
H 54 PHE H 54 PHE H 54 PHE
128 TRP – H 100C LEU –
– H 100C LEU –
H 100D GLY H 100D GLY H 100D GLY
H 100E LYS H 100E LYS H 100E LYS
H 100F PRO H 100F PRO H 100F PRO
doi:10.1371/journal.ppat.1004403.t004
Figure 9. Interdomain movements within Fv cassettes are limited. (A) Superpositions of the VH domains from two 4E10 ligand-bound structures
(2FX7.pdb, 3LH2.pdb), unbound 4E10 (4LLV.pdb), ligand-bound GEP 1 (4M8Q.pdb), unbound GEP 1 (4LRN.pdb), ligand-bound GEP 2 (4M62.pdb), ligand-
bound GEP 7 (4ODX.pdb), and unbound GEP 7 (4OB5.pdb) are shown in Ca backbone representations, colored as indicated. Residue P14H in each Fv,
chosen as a reference point to illustrate interdomain movement upon binding between 4E10 and GEPs, is shown as a sphere and colored to match the
correspondingbackbone.WhenisolatedVHdomainsaresuperimposed,theP14Hspheresarenearly coincident,indicatingthat theVHdomainstructureis
highly conserved among these Abs. (B) Fv cassettes of 4E10 and GEPs, colored as in (A), superimposed only on VL domains (oriented on the right side of
thepanel),areshownasrepresentedin(A).Inthisview,interdomainmovementscanbevisualizedastherelativemovementofVHdomains,particularlyat
the P14H reference point. (C) Orthogonal view of the P14H spheres excerpted from (B) illustrating the pattern and degree of interdomain movements.
doi:10.1371/journal.ppat.1004403.g009
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Env leading to neutralization by any of several mechanisms.
Prebinding of 4E10 to gp1403 affected b12 binding at the CD4 site
distant from the MPER (Fig. 13), indirectly demonstrating a
global conformational change consistent with this supposition.
Additional interactions between GEPs and the scaffold moiety of
T117 would also be predicted to drive rigidification of an even
greater portion of the combining site during conventional
immunization, increasing the distinction between 4E10 and a
matured Ab derived from a 4E10 GEP stimulated with T117.
T117 was the product of a cutting-edge design effort to
generate a structurally-stabilized MPER epitope with optimized
binding properties for use as a vaccine immunogen to drive 4E10
ontogeny based on the current paradigm of affinity maturation.
However, 4E10 appears to take the affinity maturation pathway
less traveled, one that contrasts, in many fundamental ways, the
current paradigm. This raises the concern that conventional
immunization protocols, based on the current paradigm of
structural stabilization of optimal binding conformers, will not
successfully re-elicit 4E10 or other unconventional Abs. Under-
standing unconventional maturation pathways then becomes
paramount for the future of molecular vaccinology, allowing
efforts to focus on re-eliciting Abs identified as the products of
conventional ontogeny in the near term while developing
Figure 10. CDR restructuring. Views from the side (A) and below (B) are shown of superpositions of isolated VH domains, in cartoon
representations, with FRW regions colored grey and b-strands indicated as arrows. HCDRs are shown in a B-factor putty representation (tube width
correlates with crystallographic Debye-Waller, or B, factor), colored by Ab. On the left in both frames is shown the superposition of VH domains from
ligand-bound 4E10 (3LH2.pdb, with green HCDRs) vs. unbound 4E10 (4LLV.pdb, with blue HCDRs), and on the right in both frames is shown the
superposition of ligand-bound structures of GEP 1 (4M8Q.pdb), GEP 2 (4M62.pdb), and GEP 7 (4ODX.pdb), all with pink HCDRs, vs. unbound GEP 1
(4LRN.pdb) and GEP 7 (4OB5.pdb), both with orange HCDRs. (C) RMSD values for VH,V L, or Fv superpositions, calculated with or without CDR
residues, are plotted for Ca atoms only (left) or all atoms (right).
doi:10.1371/journal.ppat.1004403.g010
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the long term.
Materials and Methods
Protein prediction, expression, purification and
characterization
The 4E10 heavy and light chain nucleotide sequences were
analyzed using JoinSolver [63], IMGT/V-QUEST [64,65], Ab-
Origin [66], SoDA [67] and iHMMune [68] to compositely
identify segments with the fewest nucleotide mismatches, gener-
ating a combinatorial ensemble of 12 GEPs (Fig. 1). Each derived
GEP candidate consisted of a single VL domain sequence assigned
with high confidence (IGKV3-20*01 plus IGKJ1*01), one VH
gene segment also confidently assigned (IGHV1-69*06), plus one
of six likely D segments (IGHD1-1*01, IGHD6-19*01, IGHD7-
27*01, IGHD6-25*01, IGHD1-26*01, IGHD4-17*01) and either
of two likely J segments (IGHJ4*02, IGHJ1*01). The CDR3
junctions and presumed N-nucleotide insertions in mature 4E10
were retained in the candidate GEPs. Sequences are numbered
following Kabat [24]. 4E10, eight of the 12 GEPs, and 1C6 Fvs
were engineered, expressed as inclusion bodies in E. coli
BL21(DE3) RIL cells (Invitrogen), refolded, purified, and validated
by SEC and PAGE as previously described [18]. Circular
dichroism (CD) spectra of 4E10 Fv and GEPs were measured on
a J-815 spectrometer (Jasco) at a concentration of 10 mMi n
10 mM Na2HPO4/KH2PO4 (pH=7.4). Temperature melts were
performed at 210 nM with a temperature ramp from 25uCt o
95uC at a slope of 2uC/minute, data pitch of 2uC, and delay time
of 10 s (Fig. 2). Tms were determined by nonlinear least-squares
analysis using a linear extrapolation model with Spectra Analysis
software (Jasco). Fabs of 447-52D and 4E10 were prepared by
digestion of IgG with papain (Pierce), affinity chromatography
with protein A (Pierce) and preparative SEC (Superdex 200 16/10
column; GE Healthcare); IgG 4E10 was purchased from Polymun
Scientific, and IgG 447-52D and Fab b12 were kindly provided by
Pamela Bjorkman (Caltech).
Neutralization assays
Neutralization assays (Fig. 2B) were performed using single-
round entry-competent viruses and TZM-bl cells as previously
described [53]. Percent neutralization at concentrations of
0.96 mM (4E10 and GEP Fvs) or 0.17 mM (4E10 IgG) was
calculated as previously described [18,53].
SPR interaction analyses
All SPR experiments were performed at 25uC on a Biacore
T100 instrument with the T200 sensitivity enhancement (GE
Healthcare). For analyses of the binding of 4E10 and GEP Fv
analytes to chip-captured ES ligands (Fig. 2D, Table 1), ESs at
Figure 11. GEPs binding surfaces on T117. (A) The complex of GEP 2 (orange) bound to ES T117 (red) is shown in molecular surface
representations. Non-epitope scaffold contacts are highlighted in grey. (B) The interaction partners were separated as indicated in (A) to reveal
details of the interface. T117, on the left, is shown in a red semi-transparent molecular surface representation with the NWFDIT epitope, in a licorice-
stick representation, visible within the surface. The GEP 2 Fv structure is shown on the right, colored as in (A). The NWFDIT epitope, excised from the
T117 structure, is shown as bound for reference. The footprint of GEP 2 (non-epitope contacts) on T117 is colored dark grey; the footprint of T117 to
non-epitope residues on GEP 2 is colored light grey. The position of the side-chain of F54H is indicated.
doi:10.1371/journal.ppat.1004403.g011
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following either carboxy (T117) or amine (T72, T93, T344)
biotinylation, following the manufacturer’s recommended protocol
(EZ-Link, Thermo Scientific), in a running buffer of HBS-EP+
(10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.05%
P-20; GE Healthcare) plus 0.1 mg/mL bovine serum albumin. A
reference flow cell was left blank. Duplicate 4E10 and GEP Fv
analyte injections were randomized and run at a flow rate of
50 mL/minute. Regeneration, if needed, was achieved by injection
of 10 mM glycine at 50 mL/minute followed by buffer stabiliza-
tion. Sensorgrams obtained from SPR measurements were double-
reference subtracted [69] with BIAevaluation 2.0.3 software (GE
Healthcare) employing previously described methodology [18];
data were fit with either 1:1 or steady-state binding models. For
analyses of the binding of 4E10 and GEP Fv analytes to gp1403
(Fig. 2C), gp1403 at 30 mg/mL in 10 mM sodium acetate
(pH=5.0) were direct amine coupled at a density of ,2200
RUs on a CM5 sensor chip (GE Healthcare); a reference surface
was prepared by activating and deactivating a flow cell without the
addition of protein; gp1403 were prepared as previously described
[18]. Duplicate 5 minute, 300 nM injections of 4E10 and GEP Fv
were made in HBS-EP+ at 50 mL/minute followed by 5 minutes
of dissociation, regeneration with 10 mM glycine (pH=1.5) for
5 seconds and then 6 minutes of stabilization. Assays of Fab b12
or Fab 447-52D binding to SF162 gp1403 in the presence or
absence of 4E10 Fv (Fig. 13) were conducted in HBS-EP+ buffer.
Using standard amine coupling chemistry, 1273 RUs of SF162
gp1403 were coupled to a CM5 sensor chip. A reference surface
was prepared by activating and deactivating a flow cell without the
addition of protein. Two samples were injected at a flow rate of
50 mL/minute using the dual injection command in the T100
control software (v2.0.3, GE Healthcare) with injection 1 at
5 minutes, injection 2 at 2 minutes and a final dissociation time of
5 minutes. Fab-alone curves were generated by injecting HBS-
EP+ followed by an injection of 10 nM Fab b12 or 447-52D and
double referenced by subtracting a dual injection of HBS-EP+
followed by HBS-EP+. Fab with 4E10 Fv curves were generated
by injecting 3 mM 4E10 Fv (,90 RUs bound) followed by an
Figure 12. Peptidome binding results. (A) PhIP-Seq results are plotted as 2Log10 P-values, one replicate on the abscissa, the other on the
ordinate, colored by Ab as indicated; note the discontinuity in axis scales. The top scoring 4E10 peptide derived from IP3R is highlighted with a red
arrow; one peptide, derived from the zinc finger Ran-binding domain-containing protein 3, which bound to both GEP 2 and GEP 4, is highlighted with
purple arrows. Proximity to the diagonal indicates good replicate concordance; peptides with highly discordant replicate values, falling along the
axes, were discarded from the analysis. Overall library scoring statistics are: 4E10, average=0.32, s=0.35; GEP 2, average=0.22, s=0.44; GEP 4,
average=0.25, s=0.52; 1C6, average=0.27, s=0.50. (B) The molecular surfaces of the Fv domains of 1C6 (4LCI.pdb), unbound 4E10 (4LLV.pdb) and
unbound GEP 7 (4OB5.pdb) are shown, oriented with VH domains at left and the VL domains at right. The surface is colored to show hydrophobic
patches, defined by the program HotPatch [80]; patches are colored in descending order of total area (red, orange, yellow, …). The total surface area
for red and orange hydrophobic patches is shown. The crystal structure of GEP 7 is partially disordered in HCDR1 and 3 and so patch area is
underrepresented in the calculation.
doi:10.1371/journal.ppat.1004403.g012
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4E10 Fv and double referenced by subtracting a dual injection of
3 mM 4E10 Fv followed by 3 mM 4E10 Fv. Optimal regeneration
wasachieved byinjection of10 mMglycine(pH=1.5) at a flowrate
of 50 mL/minute for 5 seconds followed by a 6 minute buffer
stabilization phase. Sensorgrams were corrected by the double-
subtraction method [69] in Scrubber 2.0b software
(BioLogic Software). Fig. 13 shows the second sample of each set
of injections with baselines zeroed just prior to the second injection.
Crystallization and crystallography
Crystals of GEPs and 4E10 Fv were grown by the hanging-drop
vapor diffusion method at 25uC with the following well solutions:
GEP 1: 25% w/v PEG 3350, 0.2 M NaCl, 0.1 M Tris (pH=8.5)
GEP 1/T117: unbuffered 12% w/v PEG 8000, 0.1 M KCl, 5%
v/v glycerol
GEP 2/T117: 1.6 M Li2SO4, 0.1 M sodium acetate (pH=5.0)
Table 5. PhIP-Seq results for 4E10 Fv.
Rank Avg. 2logP Peptide sequence Peptide source W Charge
1 12.25 SKCRVFNTTERDEQGSKV inositol 1,4,5-trisphosphate receptor type 2 0.17 21
NDFFQQTEDLYNEMKWQK
2 9.37 PPPRCISTNKCTAPEVE complement receptor type 1 isoform S precursor 0.48 +1.9
NAIRVPGNRSFFSLTEIVR
3 7.32 KAFNYRSYLTTHQRSHTG zinc finger protein 267 0.18 +4.1
ERPYKCEECGKAFNSRSY
4 7.22 PPHELTEEEKQQILHSE cytoplasmic dynein 1 intermediate chain 2 0.28 25.7
EFLSFFDHSTRIVERALSE
5 6.22 AHTGEKPYVCRECGRGFR Krueppel-related zinc finger protein 1 0.10 +5.4
QHSHLVRHKRTHSGEKPY
6 5.21 STPIEWYPDYEVEAYRRR XP_373395.2 0.49 21.7
HHNSSLNFFNWFSDHNFA
7 4.72 EQGIVGPRWWVFPSLRFAA XP_498650.1 0.71 +2
VSRPFCGAWVLSWGQAT
8 4.49 GAQPPFDAQSPLDSQPQPS nuclear fragile X mental retardation-interacting protein 1 0.42 20.9
GQPWNFHASTSWYWRQS
9 4.36 LYEEISMPLLADVRLNYLG inter-a-trypsin inhibitor heavy chain H6 precursor 0.74 22
GLVGASPWAVFPNYFGG
10 4.25 YKVDVTWTRARGASRGWR TP53-target gene 5 protein 0.12 +10.1
SRHQLKGRNGWRNSRVYK
11 4.15 AKWREVSHTFSNYPPGVR F-box only protein 44 isoform 1 0.58 +1.3
YIWFQHGGVDTHYWAGWY
12 4.07 MNPQIRNPMKAMYPGTFY APOBEC-3C 0.61 +1
FQFKNLWEANDRNETWLC
13 3.78 SGGYGSGGYGGSATPSGR ATP-dep. RNA helicase A 0.22 +4
ICAGVGGGYRGVSRGGFR
14 3.77 LMMKKRVRLEEAFEFVK dual specificity protein phosphatase 4 isoform 2 0.48 +4
QRRSIISPNFSFMGQLLQF
15 3.59 DGMYQRFLRQHVHPEETG ribonuclease 4 precursor 0.28 +2.1
GSDRYCNLMMQRRKMTLY
16 3.47 TSLEVEPFASLTEAVRSS NAD-dependent deacetylase sirtuin-3, mitochondrial isoform a 0.56 20.9
VPRLLINRDLVGPLAWHP
17 3.40 SEQFYDRSLGIMRRVLPP secreted phosphoprotein 24 0.26 +5.2
GNRRYPNHRHRARINTDF
18 3.38 MKPGFSPRGGGFGGRGGF rRNA 29-O-methyltransferase fibrillarin 0.03 +7
GDRGGRGGRGGFGGGRGR
19 3.31 NARRFSAGQWEARRGWRL ribosomal biogenesis protein LAS1L isoform 1 0.43 +2.9
FNCSASLDWPRMVESCLG
20 3.23 ESWLSRFSYAWLAPLLAR multidrug resistance-associated protein 7 isoform MRP7A 0.51 +2
GACGELRQPQDICRLPHR
doi:10.1371/journal.ppat.1004403.t005
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M Tris (pH=9.0)
GEP 7/T117: 10% w/v PEG 10000, 0.1 M NH4OAc, 0.1 M Bis-
Tris (pH=5.5)
1C6: 3.5 M sodium formate, 0.1 M Bis-Tris Propane (pH=7.0)
Crystals were cryopreserved in mother liquor containing 15%
v/v glycerol (GEP 1, GEP 1/T117, GEP 7/T117), mother liquor
containing 10% (1C6) or 20% (GEP 7) v/v glycerol, or 20% w/w
sucrose (GEP 2/T117). Diffraction data for GEP 1, 4E10, and
1C6 were collected at the Advanced Light Source beamline 5.0.2
(Lawrence Berkeley National Laboratory, Berkeley, CA) and
reduced using HKL-2000 [70] or d*TREK (Rigaku) [71].
Diffraction data for GEP 7, GEP 1/T117, GEP 7/T117 and
GEP 2/T117 were collected in house with CuKa radiation on a
R-AXIS IV++ image plate detector with HR optics (Rigaku) at
Table 6. PhIP-Seq results for GEP 2 Fv.
Rank Avg. logP Peptide sequence Peptide source W Charge
1 8.35 EGWQCSLCTYINNSELPY zinc finger Ran-binding domain-containing protein 3 0.61 25.2
CEMCETPQGSAVMQIDSL
2 6.11 PVFSFSKTSEYHDIMYPA protein O-glucosyltransferase 1 precursor 0.72 21.9
WTFWEGGPAVWPIYPTGL
3 5.74 KVTDTKPRVAEWRYGPAR transcription initiation factor TFIID subunit 1-like 0.29 21
LWYDMLGVSEDGSGFDYG
4 5.58 MTTFTEPEVVFLQSRGNE arf-GAP domain and FG repeat-containing protein 2 0.56 0
VCRKIWLGLFDARTSLVP
5 5.57 SGWGSRSQAPYGTLGAVS peroxisome proliferator-activated receptor c
coactivator-related protein 1
0.32 22.9
GGEQVLLHEEAGDSGFVS
6 5.05 MGLSRRNPSYPWLWEDG oxidized low-density lipoprotein receptor 1 isoform 1 0.53 +2.1
SPLMPHLFRVRGAVSQTYP
7 4.90 ASTLGSMPSFTARLTRGQL RING finger protein 37 isoform a 0.33 +4.1
QHLGTRGSNTSWRPGTG
8 4.72 QPNPHGNMMYTGPSHHSY histone acetyltransferase KAT6A 0.40 +3.3
MNAAGVPKQSLNGPYMRR
9 4.62 KLMGKDESTSRNRRSLSP rho guanine nucleotide exchange factor 18 isoform a 0.25 +3.1
ILPGRHSPAPPPDPGFPA
10 4.47 IQRYCNCNSSMPRPVKVA phosphofurin acidic cluster sorting protein 1 0.54 +4.9
AVGGQSYLSSILRFFVKS
11 4.44 RYDVQERHPKGKMIPVLH protein phosphatase 1 regulatory subunit 17 isoform 1 0.09 +4.3
NTDLEQKKPRRKDTPALH
12 4.39 RPGFAGPAVLDWEEWCPL hyaluronidase-3 isoform 1 precursor 0.58 +1
WAGNWGRRRAYQAASWAW
13 4.39 PIPSGSYYAPYGMPYTSM SET-binding protein isoform a 0.71 0
PMMNLGYYGQYPAPLYLS
14 4.28 NQSQGCLPARTCHSPAHS thrombospondin-3 isoform 1 precursor 0.50 +1.2
PCHIHAHCLFERNGAVSC
15 4.27 LEREVTDVDSVVGRSSVG dedicator of cytokinesis protein 8 isoform 1 0.11 +1
ERRTLAQSRRLSERALSL
16 4.23 RSRRKQHLLPPCVDEPEL forkhead box protein M1 isoform 1 0.38 +0.1
LFSEGPSTSRWAAELPFP
17 4.22 TQAFDFYSRYFAPWVGVA phenazine biosynthesis-like domain-containing protein, isoform a 0.53 21.9
EDPVTGSAHAVLSSYWSQ
18 4.17 TKWMNMKAVFGHPFSLGW palmitoyltransferase ZDHHC3 isoform 2 0.52 +1.1
ASPFATPDQGKADPYQYV
19 4.11 AGSWHPRSYAAYALKTW kiSS-1 receptor 0.68 +2.1
AHCMSYSNSALNPLLYAFL
20 4.07 EETAGEPWEDGFEAELSP NP_955358.1 0.31 25
VEQKLSALRSPLAQRPFF
doi:10.1371/journal.ppat.1004403.t006
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by molecular replacement, as implemented in the CCP4i program
suite [72–74], using 3LF6.pdb (T117), 3LH2.pdb (GEPs) and
1JP5.pbd (1C6) as initial search models. Phases were improved by
subsequent rounds of model building and refinement using
COOT [75] and REFMAC [76]. Structure validation was carried
out with PROCHECK [77], the MolProbity server [78], and the
RCSB ADIT validation server. Data collection and structure
refinement statistics are shown in Table 2. Crystals of GEP 2
alone could not be grown, despite considerable effort.
Table 7. PhIP-Seq results for GEP 4 Fv.
Rank Avg. 2logP Peptide sequence Peptide source W Charge
1 16.36 PKGKCLGSQDYLELANRF S phase cyclin A-associated protein in the
ER isoform a
0.21 +3
PQQAWEEARQFFLKKEKK
2 14.52 RPGFAGPAVLDWEEWCPL hyaluronidase-3 isoform 1 precursor 0.58 +1
WAGNWGRRRAYQAASWAW
3 13.98 ISHIQPFSFLDLESLRSL leucine-rich repeat and fibronectin type-III
domain-containing protein 2 precursor
0.50 21.8
HLDSNRLPSLGEDTLRGL
4 13.73 EGWQCSLCTYINNSELPY zinc finger Ran-binding
domain-containing protein 3
0.61 25.2
CEMCETPQGSAVMQIDSL
5 9.43 LEQNLAAAEEGPLEPAVV NP_957704.1 0.59 25.9
DAFNQAWHLFAHECPNYF
6 9.40 QAAPAPQPVFVGPAVPQG Krueppel-like factor 11 isoform a 0.68 0
AVMLVLPQGALPPPAPCA
7 8.16 EETAGEPWEDGFEAELSP NP_955358.1 0.31 25
VEQKLSALRSPLAQRPFF
8 7.40 SEALSRDPETLVGYSMVG fatty acid synthase 0.45 0
CQRAMMANRLSFFFDFRG
9 7.37 RKREKCWGRSSVMAEYG visual system homeobox 2 0.34 +4
LYGAMVRHSIPLPESILKS
10 6.65 LIKTKQRKESRFQLFMQ rho guanine nucleotide exchange factor 11 isoform 10.27 +4
EAESHPQCRRLQLRDLIIS
11 6.06 SDSSWQQQPGQPPPHSTW uncharacterized protein C14orf43 0.38 +0.2
NCHSLSLYSATKGSPHPG
12 5.98 NGKIKYECNVCAKTFGQL PR domain zinc finger protein 1 isoform 2 0.40 +5
SNLKVHLRVHSGERPFKC
13 5.97 KGKAGTPSGSSADEDTF suppressor of cytokine signaling 6 0.11 +2
SSSSAPIVFKDVRAQRPIR
14 5.75 DEMKEIQERQRDKLYERR transcriptional activator protein Pur-b 20.25 28
GGGSGGGEESEGEEVDED
15 5.64 QPPFFSKEQPQALNFGGI membrane metallo-endopeptidase-like 1 0.44 21.8
GMVIGHEITHGFDDNGRN
16 5.60 RTTENPTLERKPYSSPR zinc finger FYVE domain-containing protein 26 0.23 +3
DSSLPALTSSALAFLKSRS
17 5.60 NQSQGCLPARTCHSPAHS thrombospondin-3 isoform 1 precursor 0.50 +1.2
PCHIHAHCLFERNGAVSC
18 5.29 MAKKGCRHLVCSSGGNA serine dehydratase-like 0.48 +5
GIAAAYAARKLGIPATIVL
19 5.28 TTPFTLEGRPRGELHEQY dedicator of cytokinesis protein 8 isoform 1 0.33 +3.2
RRNTVLTTMHAFPYIKTR
20 5.26 MSAQSLPAATPPTQKPPR rho guanine nucleotide exchange factor 15 0.25 +6
IIRPRPPSRSRAAQSPGP
doi:10.1371/journal.ppat.1004403.t007
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4E10, GEP and 1C6 Fvs were coupled to beads and analyzed in
duplicate. For each Fv analyzed, 3 mg of magnetic beads
(Invitrogen M-270 Epoxy Dynabeads) were resuspended in
60 mL 0.1 M NaPO4 (pH=7.4). Beads were rocked at ambient
temperature for 24 hrs with 60 mg of each Fv in 1 M (NH4)2SO4
and then washed with 10 mM glycine in PBS to cap unreacted
epoxy groups. Activity of Fv coupled beads was confirmed by
epitope-scaffold binding prior to PhIP-Seq analyses. PhIP-Seq
analyses were performed as previously described [17,50]. Results
were plotted as replicate #1 versus replicate #2 2Log10 P-values;
highly discordant, and therefore spurious, hits falling near the axes
were excluded from analysis. 241 peptides were also discarded
because they displayed nonspecific binding to all Abs tested [17].
Peptide hydrophobicity was determined with the Sigma-Aldrich
PEPscreen Library Design Tool and overall charge at neutral
pH was determined with the Innovagen Peptide Property
Calculator.
Table 8. PhIP-Seq results for 1C6 Fv.
Rank Avg. 2logP Peptide sequence Peptide source W Charge
1 30.87 AVLKYENNVMNIRQFNCS Ser/Thr-protein phosphatase 2B catalytic subunit a isoform 1 0.81 0
PHPYWLPNFMDVFTWSLP
2 14.67 PTWDQVPPFQWSTSPFSG putative phospholipase B-like 2 isoform 1 0.64 +0.1
LLHMGQPDLWKFAPVKVS
3 13.63 QGLVLNWGLMTTRGQGLM Record removed (XP_495971.1) 0.70 +0.1
SSWGLGAHWGLPVNLGTG
4 13.54 AGNHFINVMLSHPNHTGN trans-2,3-enoyl-CoA reductase-like 0.86 +0.2
NACFPSPNYNPFTWMFFL
5 13.30 PIPSGSYYAPYGMPYTSM SET-binding protein isoform a 0.71 0
PMMNLGYYGQYPAPLYLS
6 13.21 MASNSSSCPTPGGGHLNG retinoic acid receptor a isoform 1 0.69 0
YPVPPYAFFFPPMLGGLS
7 13.11 MNPQIRNPMKAMYPGTFY APOBEC-3C 0.61 +1
FQFKNLWEANDRNETWLC
8 12.85 PENRGGFQGFGFGDGGF E3 ubiquitin-protein ligase RNF185 isoform 1 0.61 21
QMSFGIGAFPFGIFATAFN
9 12.41 MNHMLPDPGTWEEYFETFI sulfotransferase 1C2 isoform a 0.70 22.8
NGKVVWGSWFDHVKGWW
10 12.14 LQPPPSRFKQFFCLSLPS WD repeat-containing protein 27 isoform 1 0.73 +1
SWDYSLPQLPWMVNSSSF
11 11.87 TDRYMWSDASGLQECTKA tectonin b-propeller repeat-containing protein 1 0.45 22
GTKPPSLQWAWVSDWFVD
12 11.46 EYGPPRKQPKQQHGPGFW uncharacterized protein C12orf12 0.52 +3
FQPPVCSNWGCWGGPWRP
13 10.84 KVTDTKPRVAEWRYGPAR transcription init. factor TFIID subunit 1-like 0.29 21
LWYDMLGVSEDGSGFDYG
14 10.80 EQGKEPWMVVREETGRWC zinc finger protein 461 0.45 21.9
PGTWKTWGFHNNFLDNNE
15 10.57 TYGEEGLKDGHQSSHGDI dnaJ homolog subfamily B member 11 precursor 0.33 22.7
FSHFFGDFGFMFGGTPRQ
16 10.26 FWGTGLSLPSLPVSFPLQ metallothionein-1E 0.75 +2
AFCPKFRWGRTAFFSWDT
17 9.46 PVFSFSKTSEYHDIMYPA protein O-glucosyltransferase 1 0.72 21.9
WTFWEGGPAVWPIYPTGL
18 9.45 NTTWYSNDTWYGNDTWYG sodium channel protein type 4 subunit a 0.60 25
NEMWYGNDSWYANDTWNS
19 9.41 STRLPSEYIYGFGEVEHTA sucrase-isomaltase, intestinal 0.42 20.9
FKRDLNWNTWGMFTRDQ
20 9.27 SQWGQWSQVYGNPQQYGQ nucleolysin TIAR isoform 1 0.59 0
YMANGWQVPPYGVYGQPW
doi:10.1371/journal.ppat.1004403.t008
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Coordinates and structure factor amplitudes have been depos-
ited in the Protein Data Bank [79] under accession codes:
4M8Q.pdb (ligand-bound GEP 1), 4LRN.pdb (unbound GEP 1),
4M62.pdb (ligand-bound GEP 2), 4ODX.pdb (ligand-bound GEP
7), 4OB5.pdb (unbound GEP 7), and 4LCI.pdb (1C6).
Supporting Information
Movie S1 Superposition of epitope binding site contacts from
bound and unbound forms of 4E10. Residues from epitope
binding site contacts are represented as mesh, pink for bound and
yellow for unbound. The heavy chain CDR1 and CDR3 loops are
shown in cartoon representations with residues W100H, W100bH,
and F29H shown in licorice stick representations.
(M4V)
Movie S2 Superposition of epitope binding site contacts from
bound and unbound forms of GEP 7. Residues from epitope
binding site contacts are represented as mesh, pink for bound and
yellow for unbound. The heavy chain CDR1 and CDR3 loops are
shown in cartoon representations with residues W100H, W100bH,
and F29H shown in licorice stick representations.
(M4V)
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